Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of GSK1265744 in Severe Renal Impairment
NCT02354937Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabotegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoints: Area under the concentration-time curve from time zero to infinity at Day 8 and Maximum observed plasma concentration at Day 8. Started Jul 2015; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02354937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354937.